

Anant Ramaswamy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6304869/publications.pdf>

Version: 2024-02-01

94
papers

658
citations

759233

12
h-index

794594

19
g-index

95
all docs

95
docs citations

95
times ranked

862
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcome of neoadjuvant chemotherapy in locally advanced/borderline resectable gallbladder cancer: the need to define indications. <i>Hpb</i> , 2018, 20, 841-847.	0.3	50
2	Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. <i>ESMO Open</i> , 2017, 2, e000168.	4.5	48
3	Emerging role of multimodality treatment in gall bladder cancer: Outcomes following 510 consecutive resections in a tertiary referral center. <i>Journal of Surgical Oncology</i> , 2018, 117, 372-379.	1.7	29
4	COVID-19 in cancer patients on active systemic therapy – Outcomes from LMIC scenario with an emphasis on need for active treatment. <i>Cancer Medicine</i> , 2020, 9, 8747-8753.	2.8	29
5	ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country. <i>PLoS ONE</i> , 2016, 11, e0160752.	2.5	28
6	Cancer Aging Research Group (CARG) score in older adults undergoing curative intent chemotherapy: a prospective cohort study. <i>BMJ Open</i> , 2021, 11, e047376.	1.9	21
7	Capecitabine-Temozolomide in Advanced Grade 2 and Grade 3 Neuroendocrine Neoplasms: Benefits of Chemotherapy in Neuroendocrine Neoplasms with Significant ¹⁸FDG Uptake. <i>Neuroendocrinology</i> , 2021, 111, 998-1004.	2.5	19
8	Neuroendocrine Carcinoma of Gallbladder: A Step Beyond Palliative Therapy, Experience of 25 Cases. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 298-303.	1.3	18
9	Expectations and preferences for palliative chemotherapy in head and neck cancers patients. <i>Oral Oncology</i> , 2016, 63, 10-15.	1.5	16
10	Efficacy of Capecitabine Plus Irinotecan vs Irinotecan Monotherapy as Second-line Treatment in Patients With Advanced Gallbladder Cancer. <i>JAMA Oncology</i> , 2021, 7, 436.	7.1	16
11	Gemcitabine-cisplatin versus gemcitabine-oxaliplatin doublet chemotherapy in advanced gallbladder cancers: a match pair analysis. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2017, 24, 262-267.	2.6	14
12	Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors. <i>Nuclear Medicine Communications</i> , 2018, 39, 1143-1149.	1.1	14
13	A phase III randomised clinical trial of perioperative therapy (neoadjuvant chemotherapy versus) Tj ETQq1 1 0.784314 rgBT /Overlock 10 2019, 9, e028147.	1.9	14
14	Revision Surgery for Incidental Gallbladder Cancer – Challenging the Dogma: Ideal Timing and Real-World Applicability. <i>Annals of Surgical Oncology</i> , 2021, 28, 6758-6766.	1.5	14
15	Indian data on bone and soft tissue sarcomas: A summary of published study results. <i>South Asian Journal of Cancer</i> , 2016, 05, 138-145.	0.6	14
16	Dihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine based regimens: a tertiary care centre experience. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 380-386.	1.4	13
17	Neoadjuvant imatinib: longer the better, need to modify risk stratification for adjuvant imatinib. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 624-631.	1.4	12
18	Low prevalence of deficient mismatch repair (dMMR) protein in locally advanced rectal cancers (LARC) and treatment outcomes. <i>Journal of Gastrointestinal Oncology</i> , 2018, 10, 19-29.	1.4	12

#	ARTICLE	IF	CITATIONS
19	Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?. South Asian Journal of Cancer, 2016, 05, 182-185.	0.6	12
20	Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH). Oncologist, 2022, 27, 165-e222.	3.7	12
21	Early outcomes of exon 11 mutants in GIST treated with standard dose Imatinib. Annals of Translational Medicine, 2017, 5, 134-134.	1.7	11
22	Perioperative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy in Locally Advanced Gastric Cancer: Safety and Feasibility in an Interim Survival Analysis. Journal of Gastric Cancer, 2017, 17, 21.	2.5	10
23	Adherence to and Implementation of ASCO Antiemetic Guidelines in Routine Practice in a Tertiary Cancer Center in India. Journal of Oncology Practice, 2017, 13, e574-e581.	2.5	10
24	Treatment of advanced Gall bladder cancer in the real world—can continuation chemotherapy improve outcomes?. Journal of Gastrointestinal Oncology, 2017, 8, 368-376.	1.4	9
25	Clinico-pathological correlates and survival outcomes in 214 resected ampullary adenocarcinomas—are outcomes different in intestinal and pancreatobiliary subtypes with adjuvant gemcitabine?. Hpb, 2020, 22, 376-382.	0.3	9
26	Unraveling the spectrum of KIT mutations in gastrointestinal stromal tumors: An Indian Tertiary Cancer Center Experience. South Asian Journal of Cancer, 2017, 06, 113-117.	0.6	9
27	Quality of life and quality-adjusted time without toxicity in palliatively treated head-and-neck cancer patients. South Asian Journal of Cancer, 2018, 07, 249-252.	0.6	8
28	Rectal GIST—Outcomes and viewpoint from a tertiary cancer center. Indian Journal of Gastroenterology, 2016, 35, 445-449.	1.4	7
29	Gemcitabine—cisplatin (GC) as adjuvant chemotherapy in resected stage II and stage III gallbladder cancers (GBC): a potential way forward. Medical Oncology, 2018, 35, 57.	2.5	7
30	Towards standardization of management of gallbladder carcinoma with obstructive jaundice: Analysis of 113 cases over 10 years at a single institution. Journal of Surgical Oncology, 2021, 124, 572-580.	1.7	7
31	Demographics, Pattern of Care, and Outcome Analysis of Malignant Melanomas - Experience From a Tertiary Cancer Centre in India. Frontiers in Oncology, 2021, 11, 710585.	2.8	7
32	Weekly paclitaxel as metronomic palliative chemotherapy in small cell lung cancer. South Asian Journal of Cancer, 2016, 05, 067-069.	0.6	7
33	Tolerance and adverse event profile with sorafenib in Indian patients with advanced hepatocellular carcinoma. South Asian Journal of Cancer, 2017, 06, 144-146.	0.6	7
34	G8 and VES-13 as screening tools for geriatric assessment and predictors of survival in older Indian patients with cancer. Journal of Geriatric Oncology, 2022, 13, 720-730.	1.0	7
35	Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma—Results From a Tertiary Cancer Center in India. Clinical Genitourinary Cancer, 2017, 15, e345-e355.	1.9	6
36	Role of Adjuvant Chemotherapy in Resected T2N0 Gall Bladder Cancer. Journal of Gastrointestinal Surgery, 2019, 23, 2232-2238.	1.7	6

#	ARTICLE	IF	CITATIONS
37	Pathological N3 Stage (pN3/ypN3) Gastric Cancer: Outcomes, Prognostic Factors and Pattern of Recurrences After Curative Treatment. <i>Annals of Surgical Oncology</i> , 2021, , 1.	1.5	6
38	Management of colon cancer at a tertiary referral center in India - Patterns of presentation, treatment, and survival outcomes. <i>Indian Journal of Cancer</i> , 2019, 56, 297.	0.2	6
39	Neoadjuvant chemotherapy in geriatric head and neck cancers. <i>Head and Neck</i> , 2017, 39, 886-892.	2.0	5
40	Watch and Wait Approach After Neoadjuvant Chemoradiotherapy in Rectal Cancer: Initial Experience in the Indian subcontinent. <i>Indian Journal of Surgical Oncology</i> , 2021, 12, 664-670.	0.7	5
41	Treatment practices for metastatic pancreatic cancer: Can we deliver an appropriately efficacious and safe regimen in Indian patients?. <i>Indian Journal of Cancer</i> , 2018, 55, 138.	0.2	5
42	Peptide Receptor Radionuclide Therapy in the Management of Neuroendocrine Tumors (Neoplasms): Fundamentals and Salient Clinical Practice Points for Medical Oncologists. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2019, 40, 165-171.	0.2	5
43	Experience with non-cremophor-based paclitaxel-gemcitabine regimen in advanced pancreatic cancer: Results from a single tertiary cancer centre. <i>Indian Journal of Medical Research</i> , 2018, 148, 284.	1.0	5
44	Treatment outcomes of metastatic nonclear cell renal cell carcinoma: A single institution retrospective analysis. <i>South Asian Journal of Cancer</i> , 2018, 07, 226-230.	0.6	5
45	Clinical practice and outcomes in advanced gastrointestinal stromal tumor: Experience from an Indian tertiary care center. <i>South Asian Journal of Cancer</i> , 2017, 06, 110-112.	0.6	5
46	Radical D2 gastrectomy with adjuvant chemotherapy for stage IB/II/III distal gastric cancers in the era of perioperative chemotherapy: A propensity matched comparison. <i>American Journal of Surgery</i> , 2022, 223, 1055-1062.	1.8	5
47	A Case of Ruptured Adult Embryonal Sarcoma of the Liver with Excellent Outcome After Neoadjuvant Chemotherapy. <i>Journal of Gastrointestinal Cancer</i> , 2017, 48, 100-102.	1.3	4
48	Resection of Isolated Port Site Metastasis in Gall Bladder Cancers—Careful Selection and Perioperative Systemic Therapy May Improve Outcomes. <i>Indian Journal of Surgical Oncology</i> , 2018, 9, 427-431.	0.7	4
49	Addition of short course radiotherapy in newly diagnosed locally advanced rectal cancers with distant metastasis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, e70-e76.	1.1	4
50	Outcomes of exenteration in cT4 and fixed cT3 stage primary rectal adenocarcinoma: a subgroup analysis of consolidation chemotherapy following neoadjuvant concurrent chemoradiotherapy. <i>Langenbeck's Archives of Surgery</i> , 2021, 406, 821-831.	1.9	4
51	EMERALD: Emergency visit audit of patients treated under medical oncology in a tertiary cancer center: Logical steps to decrease the burden. <i>South Asian Journal of Cancer</i> , 2017, 06, 186-189.	0.6	4
52	Survey of Implementation of Antiemetic Prescription Standards in Indian Oncology Practices and Its Adherence to the American Society of Clinical Oncology Antiemetic Clinical Guideline. <i>Journal of Global Oncology</i> , 2017, 3, 346-359.	0.5	3
53	Docetaxel/Oxaliplatin/Capecitabine (TEX) triplet followed by continuation monotherapy in advanced gastric cancer. <i>Indian Journal of Cancer</i> , 2018, 55, 88.	0.2	3
54	An evaluation of early-onset fatigue and the related coping strategies in patients with gastrointestinal cancer: A prospective pilot study. <i>Indian Journal of Cancer</i> , 2018, 55, 162.	0.2	3

#	ARTICLE	IF	CITATIONS
55	Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?. Lung India, 2018, 35, 27.	0.7	3
56	Nontrial, real-world outcomes in unresectable locally advanced pancreatic cancer: Chemotherapy and chemoradiation is the standard while surgery is uncommon. Indian Journal of Cancer, 2017, 54, 530.	0.2	3
57	Early outcomes of radiofrequency ablation in unresectable metastatic colorectal cancer from a tertiary cancer hospital in India. Indian Journal of Radiology and Imaging, 2017, 27, 200-206.	0.8	3
58	Calculation of a clinical predictive factors identifying peritoneal disease on a staging laparoscopy in gastric cancers. South Asian Journal of Cancer, 2019, 08, 166-167.	0.6	3
59	Prognostic value of imaging-based parameters in patients with intermediate-stage hepatocellular carcinoma undergoing transarterial radioembolization. Nuclear Medicine Communications, 2021, 42, 337-344.	1.1	3
60	Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed+carboplatin chemotherapy. Ecancermedicalsecience, 2017, 11, 776.	1.1	2
61	Real-World Long-Term Outcomes with Perioperative EOX in D2 Gastrectomy: a Meaningful Look While We Switch to FLOT-4. Journal of Gastrointestinal Cancer, 2020, 51, 703-708.	1.3	2
62	Tamoxifen and fulvestrant induced steatohepatitis with cirrhosis: A rare case report. South Asian Journal of Cancer, 2019, 08, 225-240.	0.6	2
63	Systemic chemotherapy and short-course radiation in metastatic rectal cancers: A feasible paradigm in unresectable and potentially resectable cancers. South Asian Journal of Cancer, 2019, 08, 092-097.	0.6	2
64	Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers. South Asian Journal of Cancer, 2018, 07, 219-222.	0.6	2
65	Outcomes with second-line chemotherapy in advanced pancreatic cancers: A retrospective study from a tertiary cancer center in India. Indian Journal of Cancer, 2018, 55, 144.	0.2	2
66	Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study. South Asian Journal of Cancer, 2019, 08, 22-26.	0.6	2
67	Presentation and Outcomes with First-Line Chemotherapy in Advanced Cholangiocarcinomas—A Relatively Rare Component of Biliary Tract Cancers in India. South Asian Journal of Cancer, 2020, 09, 209-212.	0.6	2
68	Radiotherapy for locally advanced unresectable gallbladder cancer - A way forward. Journal of Cancer Research and Therapeutics, 2022, 18, 147-151.	0.9	2
69	Technically unresectable recurrent oral cancers: Is NACT the answer?. Oral Oncology, 2016, 56, e12-e14.	1.5	1
70	Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?. Chemotherapy Research and Practice, 2017, 2017, 1-4.	1.6	1
71	What drives the wheel towards long-term outcome in advanced GIST, its size, genotype or may be a pill or two of imatinib?. Translational Gastroenterology and Hepatology, 2017, 2, 94-94.	3.0	1
72	Prognostic value of lung shunt fraction in hepatocellular carcinoma and unresectable liver dominant metastatic colorectal cancer undergoing transarterial radioembolisation. Nuclear Medicine Communications, 2021, Publish Ahead of Print, 24-31.	1.1	1

#	ARTICLE	IF	CITATIONS
73	Activation of phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway and response to everolimus in endocrine receptor-positive metastatic breast cancer – A retrospective pilot analysis and viewpoint. South Asian Journal of Cancer, 2017, 06, 102-105.	0.6	1
74	A prospective analysis of chemotherapy-induced nausea and vomiting in gastrointestinal cancers: Results from a tertiary cancer center.. Journal of Clinical Oncology, 2020, 38, 12111-12111.	1.6	1
75	Gastrointestinal Stromal Tumor – An Overview. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 809-818.	0.2	1
76	Chemotherapy-Induced Nausea and Vomiting in Gastrointestinal Cancer Patients: Do We Need to Revisit Guidelines?. South Asian Journal of Cancer, 2020, 09, 245-249.	0.6	1
77	Red Cell Distribution Width and Gallbladder Cancer: Is It Really Useful?. Journal of Gastrointestinal Cancer, 2022, 53, 995-1005.	1.3	1
78	An Analysis of Tolerance and Early Survival Outcomes with Perioperative Modified FLOT in Gastric Cancers. South Asian Journal of Cancer, 0, , .	0.6	1
79	Addressing the Needs of Older Adults With Cancer in Low- and Middle-Income Settings. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 384-393.	3.8	1
80	Development of a New Tool to Assess the Quality of Life of Patients with Hand-Foot Syndrome Receiving Capecitabine-Based Therapy: A Pilot Study. South Asian Journal of Cancer, 2022, 11, 019-023.	0.6	1
81	ASO Visual Abstract: Pathologic N3 Stage (pN3/ypN3) Gastric Cancer – Outcomes, Prognostic Factors, and Pattern of Recurrences after Curative Treatment. Annals of Surgical Oncology, 2021, 28, 587.	1.5	0
82	Dihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine-based regimens: A retrospective tertiary care centre experience.. Journal of Clinical Oncology, 2016, 34, 712-712.	1.6	0
83	Survey of implementation of antiemetic prescription standards in Indian oncology practices and adherence to ASCO's antiemetic clinical guideline.. Journal of Clinical Oncology, 2016, 34, e18230-e18230.	1.6	0
84	Poor risk advanced renal cell carcinoma: Outcomes from a registry in a tertiary cancer center. Indian Journal of Medical and Paediatric Oncology, 2017, 38, 311.	0.2	0
85	Upfront short course radiotherapy (SCRT) in metastatic rectal cancer (mRC): A way forward.. Journal of Clinical Oncology, 2017, 35, 3570-3570.	1.6	0
86	Tyrosine kinase inhibitor versus physician choice chemotherapy in second-line epidermal growth factor receptor mutation non-small cell lung cancer: Post hoc analysis of randomized control trial. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 493.	0.2	0
87	Up-front short-course radiotherapy and systemic chemotherapy for locally advanced rectal cancers with distant metastasis: Does it provide meaningful benefit?. Journal of Clinical Oncology, 2018, 36, 778-778.	1.6	0
88	Early survival outcomes in stage I-III operated colon cancer patients from a low prevalence, lower-middle income country: The Indian experience.. Journal of Clinical Oncology, 2018, 36, 857-857.	1.6	0
89	Prevalence of MSI status in locally advanced rectal cancer and its correlation with response to neoadjuvant therapy and survival.. Journal of Clinical Oncology, 2018, 36, e15668-e15668.	1.6	0
90	Influence of hypothyroidism post chemo radiation on outcomes in head and neck cancer.. Journal of Clinical Oncology, 2018, 36, e18066-e18066.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Adjuvant chemotherapy in stage II–III operated colon cancer patients from a nontrial cohort in a low colon cancer prevalence country with predominant use of modified CAPOX. South Asian Journal of Cancer, 2019, 08, 160-165.	0.6	0
92	Comparison of treatment plans feasible through AI enabled multidisciplinary online tumor board solution versus NCCN-based clinical decision support system (CDSS).. Journal of Clinical Oncology, 2020, 38, 816-816.	1.6	0
93	Older patients with cancer require and deserve more!. Indian Journal of Cancer, 2021, 58, 479.	0.2	0
94	The Prevalence of BRAF, PIK3CA, and RAS Mutations in Indian Patients with Colorectal Cancer. South Asian Journal of Cancer, 0, , .	0.6	0